Skip to content
  • Home
  • Journalists
    • Headlines
  • Community
    • Businesses
    • Jobs
    • Learning
    • Marketplace
  • Store
(@)

How Ozempic Maker Novo Nordisk Lost Its Shine

The pioneering Danish drugmaker was once the most valuable company in Europe, but analysts say a number of missteps reversed its fortunes.

Eshe Nelson
Author: Eshe Nelson

Written by

Eshe Nelson

in

Appointments and Executive Changes, Company Reports, Drugs (Pharmaceuticals), GLP-1 RAs (Drug), Ozempic (Drug), Regulation and Deregulation of Industry, Stocks and Bonds
←‘Fleetwood Mac’ at 50: A Marvel of Serendipity and Perfectionism
Cannonball with Wesley Morris: Beyoncé Isn’t Giving Up on America→

More posts

  • Protesters, leaders push back against DHS over Newark detention facility conditions

  • Goldman and Lander spar hard over Israel

  • Snowflake climbs after Q1 results top expectations, guidance gets a boost

  • Synopsys drops despite better than expected Q2 results, big boost to full-year guidance

About Us


Support Us

Trademark & Copyright 1998 – 2025 · MOSAEC

  • Facebook
  • Instagram
  • LinkedIn
  • YouTube